Streetbeat News

SAVA

Cassava Sciences, Inc.

https://www.cassavasciences.com

Industry

Biotechnology

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Open

26.40

Mkt cap

1.2B

Volume

1.6M

High

27.16

P/E Ratio

-8.95

52-wk high

42.20

Low

24.65

Div yield

N/A

52-wk low

8.79

Cassava Sciences has received a Notice of Allowance for a US patent application titled 'Alzheimer's Disease Assay In A Living Patient,' which is designed to determine the likelihood of Alzheimer's Disease or Mild Cognitive Impairment due to AD.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 4:03 pm

Cassava Sciences shares are trading higher after HC Wainwright maintained a Buy rating on the stock and raised its price target from $124 to $131.

Portfolio Pulse from Benzinga Newsdesk

May 17, 2024 | 7:34 pm

Cassava Sciences (NYSE:SAVA) has seen a 3.41% decrease in its short percent of float, now at 30.84%. This indicates a potential shift in market sentiment. The company's short interest remains higher than its peers, with 13.87 million shares sold short, taking an average of 16.17 days to cover.

Portfolio Pulse from Benzinga Insights

May 17, 2024 | 3:30 pm

HC Wainwright & Co. has maintained a Buy rating on Cassava Sciences (NASDAQ:SAVA) and raised the price target from $124 to $131.

Portfolio Pulse from Benzinga Newsdesk

May 17, 2024 | 12:12 pm

Cassava Sciences reported Q1 earnings with losses of $(0.43) per share, surpassing the analyst consensus estimate of $(0.46) and marking a 25.86% improvement over last year's $(0.58) per share loss.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:02 pm

Cassava Sciences announced that the proceeds warrant distribution represents the sale of approximately 5.7 million shares at a price of $22 per share.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 3:03 pm

Cassava Sciences has successfully raised over $125 million through the distribution of warrants. This financial move is significant for the company's funding and future research endeavors.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 3:01 pm

Cassava Sciences announced it has raised $125 million through a warrant distribution. This financial move could significantly impact the company's research and development capabilities, potentially accelerating its pipeline projects.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 3:01 pm

JPMorgan Chase & Co. shares fell by 5.1% despite beating first-quarter earnings and revenue expectations, with other stocks experiencing significant movements in Friday's mid-day session. Notable gainers include PaxMedica, EZGO Technologies, and Allarity Therapeutics, among others, with various reasons for their stock movements. Conversely, several companies faced declines, such as Motus GI Holdings, Lixiang Education, and Monogram Orthopaedics, each with specific challenges impacting their stock prices.

Portfolio Pulse from Avi Kapoor

April 12, 2024 | 6:47 pm

Cassava Sciences (NYSE:SAVA) has seen a decrease in short interest, with 11.76 million shares sold short, representing 29.54% of its float. This is a 3.46% drop since the last report, indicating a potential shift in market sentiment towards the stock. The current short interest suggests it would take approximately 23.47 days for traders to cover their positions, based on average trading volumes. Comparatively, Cassava's short interest is higher than its peer group average of 12.46%, suggesting more bearish sentiment towards SAVA than its peers.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 4:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.